Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection - Concepedia

Concepedia

Publication | Open Access

Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection

DOI Full Paper Access

157

Citations

28

References

2019

Year

Yeming Wang, Guohui Fan, Alex P. Salam, Peter Horby, Frederick G. Hayden, Cheng Chen, Jianguang Pan, Jing Zheng, Binghuai Lu, Liping Guo,

The Journal of Infectious Diseases

Abstract

Favipiravir and oseltamivir combination therapy may accelerate clinical recovery compared to oseltamivir monotherapy in severe influenza, and this strategy should be formally evaluated in a randomized controlled trial.

References

	Year	Citations
A Proportional Hazards Model for the Subdistribution of a Competing Risk Jason P. Fine Journal of the American Statistical Association PrognosisRare Event EstimationRisk MetricRisk AnalysisEmerging Risk	1999	13.2K
Estimates of global seasonal influenza-associated respiratory mortality: a modelling study A. Danielle Iuliano, Katherine Roguski, Howard H. Chang, The Lancet Infectious Disease ModellingGlobal HealthEpidemiological DynamicModelling StudyComputational Epidemiology	2017	2.9K
Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents Frederick G. Hayden, Norio Sugaya, Nobuo Hirotsu, New England Journal of Medicine	2018	878
Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa Timothy M. Uyeki, Henry H. Bernstein, John S. Bradley, Clinical Infectious Diseases Disease OutbreakInfectious Diseases SocietyClinical Practice GuidelinesPreventive MedicineHealthcare-associated Infection	2018	724
Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa Timothy M. Uyeki, Henry H. Bernstein, John S. Bradley, Clinical Infectious Diseases Infectious Disease EpidemiologyEmerging Infectious DiseasesMedicineClinical EpidemiologyDisease Outbreak	2019	391
Corticosteroid Treatment in Critically Ill Patients with Pandemic Influenza A/H1N1 2009 Infection Sung-Han Kim, Sang‐Bum Hong, Sung-Choel Yun, American Journal of Respiratory and Critical Care Medicine	2011	221
T-705 (favipiravir) activity against lethal H5N1 influenza A viruses Maki Kiso, Kazumi Takahashi, Yuko Sakai‐Tagawa, Proceedings of the National Academy of Sciences Purine NucleosidesMedicineImmunologyAntiviral Drug DevelopmentAntiviral Therapy	2009	212
Mechanism of Action of T-705 Ribosyl Triphosphate against Influenza Virus RNA Polymerase Hidehiro Sangawa, Takashi Komeno, Hiroshi Nishikawa, Antimicrobial Agents and Chemotherapy Enzyme KineticsVirus StructureViral ReplicationEnzyme Kinetic AnalysisBiochemistry	2013	186
Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted Thi Huyen Tram Nguyen, Jérémie Guedj, Xavier Anglaret, PLoS neglected tropical diseases	2017	185
Adjuvant Corticosteroid Treatment in Adults With Influenza A (H7N9) Viral Pneumonia* Bin Cao, Hainv Gao, Boping Zhou, Critical Care Medicine	2016	175

Page 1